Compare CDMOs following ICH guidelines for pharmaceutical quality (Q series), analytical methods, stability testing, and impurity control.
3 companies listed
The International Council for Harmonisation (ICH) develops guidelines that harmonize pharmaceutical regulatory requirements across the US, EU, and Japan (the three founding regulatory regions). ICH guidelines cover quality (Q series), safety (S series), efficacy (E series), and multidisciplinary topics (M series). For CDMOs, the Q series is most directly relevant: Q7 (GMP for APIs), Q8 (pharmaceutical development), Q9 (quality risk management), Q10 (pharmaceutical quality system), Q11 (drug substance development), Q12 (lifecycle management).
ICH compliance is not a formal certification but rather adherence to internationally recognized guidelines. CDMOs that follow ICH guidelines produce documentation and data that are accepted by regulatory agencies worldwide, facilitating global filings. ICH Q7 GMP for APIs is particularly important -- it defines the minimum quality standards expected for active pharmaceutical ingredient manufacturing.
United States
UPM Pharmaceuticals is a U.S.-based CDMO specializing in late-stage commercial manufacturing of oral solid dose products. Operating from a 450,000 sq.ft. cGMP FDA-registered facility in Bristol, Tennessee, UPM is a family-owned company with 25+ years of experience. They handle DEA-controlled substances and provide services from technology transfer and scale-up through commercial manufacturing. Capabilities include formulation development, analytical development, coated tablet manufacturing, pharmaceutical serialization, aggregation, and full packaging and warehousing.
China
Chengda Pharmaceutical positions itself as a CDMO partner with over two decades of experience, focusing on process development and industrialization for key pharmaceutical intermediates and APIs. Its core strengths lie in a combination of regulatory compliance, flexible production capabilities, and strategic expansion into high-growth therapeutic areas. Regulatory Compliance and Global Market Access Chengda has established a robust quality management system that integrates drug cGMP (ICH Q7) with ISO9001 and other standards, enabling it to meet the stringent requirements of multinational pharmaceutical companies. The company has successfully passed on-site inspections by regulatory agencies including the U.S. FDA, China's NMPA, Japan's PMDA, and Malaysia's NPRA. Its API registration applications have also passed technical reviews by authorities such as the FDA, EDQM, and Health Canada. This compliance infrastructure allows Chengda to embed its CDMO services directly into the innovation chains of its clients, supporting both clinical development and commercial manufacturing. Production Flexibility and End-to-End Service Capability The company offers a broad service range spanning from kilogram to ton-scale production of key intermediates and APIs, covering process R&D, optimization, analytical method development and validation, stability studies, and customized manufacturing. Its production facilities are designed for diverse chemical reactions, featuring capabilities for ultra-low temperature reactions (down to -78°C), high-pressure hydrogenation, anhydrous and oxygen-free synthesis, and chiral compound synthesis. With a total reaction volume of approximately 950,000 liters and multiple clean rooms, Chengda can accommodate different scales and technical requirements, from preclinical studies to commercial launch. Strategic Positioning in High-Growth Modalities Chengda has made strategic moves into two high-growth areas: small-molecule GLP-1 intermediates for weight management and oligonucleotide (small nucleic acid) intermediates. The company has progressed from laboratory development to commercial-scale readiness for GLP-1 intermediates and can supply high-quality monomers and delivery system intermediates for siRNA and ASO drugs. This expansion leverages its existing expertise in complex chemical synthesis and positions the company to capture demand in these rapidly expanding therapeutic categories. Proven Track Record with Global Clients Chengda's client base includes multinational pharmaceutical companies such as Incyte, Helsinn, Eli Lilly/Evonik, Gilead, and GSK. Its ability to maintain long-term relationships and expand the scope of collaboration reflects a consistent delivery record and growing client trust in its technical and manufacturing capabilities
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.